Glaukos Co. (NYSE:GKOS) Shares Acquired by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its holdings in Glaukos Co. (NYSE:GKOS) by 6.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 413,680 shares of the medical instruments supplier’s stock after purchasing an additional 26,510 shares during the quarter. Bank of New York Mellon Corp owned 0.82% of Glaukos worth $48,959,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Glaukos by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier’s stock valued at $500,576,000 after buying an additional 72,159 shares during the period. Brown Capital Management LLC boosted its holdings in Glaukos by 3.4% in the fourth quarter. Brown Capital Management LLC now owns 2,697,794 shares of the medical instruments supplier’s stock valued at $214,448,000 after purchasing an additional 89,420 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Glaukos by 3.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 923,526 shares of the medical instruments supplier’s stock valued at $73,412,000 after purchasing an additional 31,213 shares during the period. Primecap Management Co. CA grew its stake in Glaukos by 23.7% during the 4th quarter. Primecap Management Co. CA now owns 790,035 shares of the medical instruments supplier’s stock worth $62,800,000 after purchasing an additional 151,415 shares in the last quarter. Finally, Iron Triangle Partners LP increased its holdings in Glaukos by 75.6% during the 1st quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock worth $40,500,000 after purchasing an additional 184,919 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

GKOS has been the subject of a number of analyst reports. Piper Sandler boosted their price objective on Glaukos from $110.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Citigroup cut shares of Glaukos from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $130.00 to $132.00 in a report on Wednesday, July 10th. Truist Financial restated a “buy” rating and issued a $145.00 price objective (up from $141.00) on shares of Glaukos in a report on Thursday, August 1st. BTIG Research boosted their target price on shares of Glaukos from $131.00 to $139.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Wells Fargo & Company raised their price target on Glaukos from $120.00 to $135.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $128.45.

Insider Buying and Selling at Glaukos

In related news, Director Aimee S. Weisner sold 25,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the director now owns 30,119 shares of the company’s stock, valued at $3,614,280. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Glaukos news, COO Joseph E. Gilliam sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total value of $646,800.00. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $13,216,581.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Aimee S. Weisner sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the sale, the director now owns 30,119 shares of the company’s stock, valued at approximately $3,614,280. The disclosure for this sale can be found here. Over the last three months, insiders have sold 41,000 shares of company stock worth $4,990,740. 6.40% of the stock is owned by company insiders.

Glaukos Stock Up 1.0 %

Shares of NYSE GKOS opened at $133.89 on Friday. The business has a 50-day moving average price of $122.24 and a 200 day moving average price of $107.69. The stock has a market cap of $6.74 billion, a PE ratio of -46.49 and a beta of 1.05. The company has a quick ratio of 4.68, a current ratio of 5.48 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 52-week low of $59.22 and a 52-week high of $136.36.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business had revenue of $95.70 million for the quarter, compared to analyst estimates of $88.86 million. During the same period last year, the firm posted ($0.55) earnings per share. The company’s revenue for the quarter was up 19.0% compared to the same quarter last year. Equities research analysts forecast that Glaukos Co. will post -2.25 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.